EYPT is down -69.49% to $4.50 as of 9:36 a.m. ET Monday, versus Friday's regular-session close of $14.75, during regular trading after a premarket halt. The primary catalyst is topline Phase 3 LUGANO data showing Duravyu missed its primary endpoint for change in best corrected visual acuity versus aflibercept in wet AMD.

Upcoming Phase 2 data readouts and potential regulatory advancements for lead candidate ABCL635 represent major near-term catalysts in the vasomotor symptoms market. Strategic positioning through a proprietary AI-driven antibody discovery platform provides competitive differentiation in addressing complex targets and novel modalities.

AbCellera Biologics shares gained approximately 76% over the 30-day period through the latest available close, rising from $6.47 on July 17, 2026, to $11.38 on August 14, 2026. The decisive catalyst was positive Phase 2 data for ABCL635, an investigational antibody treatment for moderate-to-severe vasomotor symptoms associated with menopause.

Lead candidate INO-3107 for recurrent respiratory papillomatosis (RRP) faces a key FDA Prescription Drug User Fee Act (PDUFA) decision on October 30, 2026, under accelerated approval review, representing a potential near-term regulatory catalyst. Company maintains cash runway into late first quarter 2027 following recent equity financing, supporting operations through the anticipated regulatory outcome and potential commercial preparations.

Humacyte shares fell approximately 11.3% in the 30 days ended August 14, 2026, based on available closing prices of $0.6816 on July 15 and $0.6048 on August 14. The decline sharpened after second-quarter results missed consensus revenue and EPS expectations, renewing concerns about SYMVESS commercialization and cash burn.

The selected price target is $3.00 , the most conservative published 12-month analyst target for RenovoRx, Inc. (NASDAQ: RNXT) . With the latest regular-session close near $1.40 , reaching $3 would require a gain of roughly 114% and would lift the market capitalization to about $135 million .

RenovoRx shares climbed about 62% over the trailing 30 days, from $0.8653 at the July 17, 2026 close to $1.40 at the August 14, 2026 close. The advance accelerated after record second-quarter revenue of $909,000, up 61% sequentially and 115% year over year, alongside a narrower-than-expected adjusted net loss.

Selected price target: $1.00 per share, a psychological and Nasdaq listing-compliance level that implies a roughly 490% gain from the latest close near $0.17. Strongest bullish factors: potential government stockpile procurement for Entolimod, international government interest, and the company's new CDMO subsidiary.

HALO shares advanced approximately 30.1% during the 30 days ended August 14, 2026, based on an available price of $98.63 versus a closing price of $75.82 on July 15. The move was driven primarily by second-quarter 2026 results released August 6, including revenue of $481 million and non-GAAP diluted EPS of $2.28.

INO is up +13.33% during Friday’s regular session, trading near $1.02 versus Thursday’s close of $0.90. The move is primarily a continuation of Thursday’s post-earnings, analyst-upgrade momentum rather than a fresh company-specific headline.

The central question is whether Xencor, Inc. ( XNCR ) can reach a $30 stock price target , roughly 30% above recent trading near $23. The strongest bullish factor is operational momentum: second-quarter results beat expectations by a wide margin, and several clinical catalysts are approaching.

Xencor’s XmAb protein engineering platform positions the company for potential advances in bispecific antibody therapies targeting cancer and autoimmune diseases, with multiple programs in clinical development. Upcoming clinical data readouts and regulatory milestones for candidates such as XmAb942 in inflammatory bowel disease (IBD) represent key near-term catalysts that could influence investor sentiment.

XNCR advanced approximately 50.2% in the 30-day period, rising from a $14.98 close on July 15, 2026, to roughly $22.50 in mid-August. The move accelerated after Xencor announced that Phase 1 expansion-cohort data for XmAb819 in advanced clear cell renal cell carcinoma was selected for an oral presentation at ESMO 2026.

INO is trading up +2.42% at $0.9219 during regular market hours as of roughly 10:09 a.m. ET, compared with Thursday’s close of $0.9001. The advance extends Thursday’s +16.90% jump after Jefferies upgraded Inovio to Buy from Hold and raised its price target to $3.00 from $1.80 on positive FDA review progress for INO-3107.

ARS Pharmaceuticals (SPRY) is trading down -10.25% at $5.48 in early regular trading, versus a $6.10 close on Aug 13. The move follows Q2 results released after the prior close: EPS came in at -$0.63, missing the -$0.50 consensus, while revenue of $33.7M beat the $31.5M estimate.

OBX traded at $21.50 as of 11:39 a.m. ET on Aug. 13, down -$6.50 or -23.21% from the previous close of $28.00, during regular trading. The decline extends a sharp post-merger pullback: after the Galera reverse-merger debut and $350 million PIPE, shares fell -14.89% on Aug. 12 and indicated lower premarket.

Inovio shares traded at $0.8805 as of 10:08 a.m. ET on Thursday, up +14.35% from Wednesday's $0.77 close, with the gain occurring during regular trading. The rally accelerated after a modest premarket indication near +4%, with buying strengthening after the open.

CORT (Corcept Therapeutics Incorporated) demonstrated strong recent momentum driven by robust Q2 2026 revenue growth of 32% year-over-year and upward revisions to full-year guidance. CPK (Chesapeake Utilities Corporation) has delivered steady performance typical of regulated utilities, supported by consistent earnings growth and infrastructure investments in recent quarters.

Corcept Therapeutics ( CORT ) has demonstrated stronger recent momentum with substantial year-to-date gains compared to OPKO Health ( OPK ). CORT reported robust second-quarter revenue growth of 32% year-over-year, supporting positive sentiment in recent market activity.

Selected price target: $20 per share, roughly 54% above recent trading levels near $13. Strongest bullish factor: DURAVYU, the company's lead sustained-delivery eye treatment, is advancing through pivotal Phase 3 trials, with wet AMD data anticipated beginning in August 2026.